<?xml version="1.0" encoding="UTF-8"?>
<p>Cholinesterases (ChEs) inhibitors can increase the levels of ACh and contribute to upregulate the cholinergic tone in neurons, partially ameliorating cognitive symptoms. AChE is a particularly attractive target to address AD-related symptoms, not only for its catalytic functions but also for the effects on A
 <italic>Î²</italic> precipitation, plaque formation [
 <xref rid="B29" ref-type="bibr">29</xref>], and inflammation. As discussed before, a few compounds have made their appearance in the market, like Donepezil or Rivastigmine (
 <bold>2</bold> and 
 <bold>4</bold>, 
 <xref ref-type="fig" rid="fig1">Figure 1</xref>), which were approved for the treatment of mild-to-moderate AD symptoms.
</p>
